IDEAYA Biosciences Inc

IDYA

Company Profile

  • Business description

    IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275/GSK959 (Werner Helicase), IDE161 (PARG), and IDE705/GSK101 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.

  • Contact

    5000 Shoreline Court
    Suite 300
    South San FranciscoCA94080
    USA

    T: +1 650 443-6209

    https://www.ideayabio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2026

    Employees

    131

Stocks News & Analysis

stocks

Undervalued by 17%, this US cybersecurity leader is a buy for 2026

Here’s a wide-moat company with strong secular tailwinds in a promising industry—and an attractive stock price, too.
stocks

Tough conditions for ASX listed wagering leader

Wagering continues to be challenged in Australia.
stocks

Chart of the Week: Inflation fears dampen sentiment on retailers

Rising inflation is the fly in the ointment.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,045.9027.80-0.31%
CAC 408,362.09118.631.44%
DAX 4025,261.64134.180.53%
Dow JONES (US)49,504.07237.960.48%
FTSE 10010,124.6079.910.80%
HKSE26,231.7982.480.32%
NASDAQ23,671.35191.330.81%
Nikkei 22551,939.89822.631.61%
NZX 50 Index13,696.2520.61-0.15%
S&P 5006,966.2844.820.65%
S&P/ASX 2008,717.8029.10-0.33%
SSE Composite Index4,120.4337.450.92%

Market Movers